Distinguished in Lung Metastases

Tiziana Comito

Via Manzoni 56, Rozzano, 
Milan, IT 
Distinguished in Lung Metastases
Via Manzoni 56, Rozzano, 
Milan, IT 
OverviewLocationsClinical Research

Overview

Tiziana Comito practices in Milan, Italy. Ms. Comito is rated as a Distinguished expert by MediFind in the treatment of Lung Metastases. Her top areas of expertise are Lung Metastases, Pancreatic Cancer, Liver Cancer, Pancreaticoduodenectomy, and Mastectomy.

Her clinical research consists of co-authoring 94 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles in the study of Lung Metastases.

Gender
Female

Locations

Via Manzoni 56, Rozzano, Milan, 20089, Italy
Other Locations
Rozzano, 20089, Italy
1 Radiotherapy And Radiosurgery, Via Manzoni 56, Via Manzoni, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Phase III Trial on Stereotactic Body Radiation Therapy (SBRT) Versus Microwave Ablation (MWA) for Inoperable Colorectal Liver Metastases (CLM)
A Randomized Phase III Trial on Stereotactic Body Radiation Therapy (SBRT) Versus Microwave Ablation (MWA) for Inoperable Colorectal Liver Metastases (CLM)
Enrollment Status: Terminated
Publish Date: September 16, 2022
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
Phase II Trial Evaluating Stereotactic Body Radiation Therapy (SBRT) After Induction Chemotherapy for Patients With Locally Advanced Unresectable Pancreatic Cancer
Phase II Trial Evaluating Stereotactic Body Radiation Therapy (SBRT) After Induction Chemotherapy for Patients With Locally Advanced Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Combination product
Study Drug: Chemotherapy
Study Phase: Phase 2
View 1 Less Clinical Trial

94 Total Publications

Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR).
Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR).
Journal: Cancers
Published: June 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Comito's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile